Status
Conditions
Treatments
About
The objective of this study is to obtain outcomes following dissection repair with the Tack Endovascular System in a broad population of patients undergoing endovascular treatment of lesions within the superficial femoral, popliteal, peroneal, and/or tibial arteries.
Full description
The purpose of this post-market study is to obtain outcomes following dissection repair with the Tack Endovascular System in a broad population of patients undergoing endovascular treatment of lesions within the superficial femoral, popliteal, peroneal, and/or tibial arteries.
The Tack Endovascular System has been shown to effectively repair dissection and improve outcomes in clinical studies. Additional data, such as clinical utility of the Tack Endovascular System with the combined use of adjunctive therapies - other than balloon angioplasty alone, is needed.
Patients with claudication or CLI, who meet Rutherford classification 3, 4, or 5 criteria if ATK and Rutherford classification criteria 4 or 5 if BTK, who have undergone an above the knee (ATK) or below the knee (BTK) endovascular procedure utilizing adjunctive therapies other than balloon angioplasty alone which are then followed by PTA and IVUS, and have an arterial dissection requiring repair.
Approximately 100 subjects will be enrolled in up to 10 sites. The enrollment will be capped as follows:
After enrollment of planned 100 subjects and interim analysis, the study may enroll up to 200 additional subjects at up to 20 additional sites, with each site limited to 15% of total enrollment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
General Inclusion Criteria
Age ≥ 18 years
Willingness to comply with study follow-up evaluations at the predefined time intervals
Signs the written informed consent
Meets Rutherford classification criteria:
Angiographic Inclusion Criteria
A de novo or restenotic, non-stented target lesion with pre-intervention stenosis or occlusion (by visual estimate)
ATK Lesions:
BTK Lesions:
Post-IVUS Inclusion Criteria
Exclusion criteria
General Exclusion Criteria
Subject is known to be breastfeeding, pregnant or planning to become pregnant during the study
Anticipated life expectancy < 12 months
Known COVID positive test within 14 days and active symptoms
Known renal disease that precludes contrast administration
Presence of a wound that in the opinion of the investigator cannot be healed with transmetatarsal amputation (TMA)
Contraindication to anticoagulation and/or antiplatelet therapy
Known allergy to nitinol (nickel and/or titanium)
Known allergy to contrast media that cannot be adequately pre-medicated prior to index procedure
Previous or planned surgical or interventional procedure within 3 days before or 30 days after the index procedure.
Note: this excludes successful inflow artery treatment within the same hospitalization or a documented pre-planned minor amputation.
Subject has any condition that in the opinion of the investigator precludes the subject from participation
Angiographic Exclusion Criteria
6 participants in 2 patient groups
Loading...
Central trial contact
Alicia Sherwin
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal